TY - JOUR
T1 - Evaluating new treatments for anaplastic thyroid cancer
AU - Coca-Pelaz, Andrés
AU - Rodrigo, Juan P.
AU - Lopez, Fernando
AU - Shah, Jatin P.
AU - Silver, Carl E.
AU - Al Ghuzlan, Abir
AU - Menke-van der Houven van Oordt, C. Willemien
AU - Smallridge, Robert C.
AU - Shaha, Ashok R.
AU - Angelos, Peter
AU - Mendenhall, William M.
AU - Piazza, Cesare
AU - Olsen, Kerry D.
AU - Corry, June
AU - Tufano, Ralph P.
AU - Sanabria, Alvaro
AU - Nuyts, Sandra
AU - Nathan, Cherie Ann
AU - Vander Poorten, Vincent
AU - Dias, Fernando Luiz
AU - Suarez, Carlos
AU - Saba, Nabil F.
AU - de Graaf, Pim
AU - Williams, Michelle D.
AU - Rinaldo, Alessandra
AU - Ferlito, Alfio
N1 - Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Introduction: Anaplastic thyroid cancer (ATC) is one of the most lethal diseases known to humans with a median survival of 5 months. The American Thyroid Association (ATA) recently published guidelines for the treatment of this dreadful thyroid malignancy. Areas covered: This review presents the current therapeutic landscape of this challenging disease. We also present the results from trials published over the last five years and summarize currently active clinical trials. Expert opinion: Recent attempts to improve the prognosis of these tumors are moving toward personalized medicine, basing the treatment decision on the specific genetic profile of the individual tumor. The positive results of dabrafenib and trametinib for ATC harboring the BRAF V600E mutation have provided a useful treatment option. For the other genetic profiles, different drugs are available and can be used to individualize the treatment, likely using drug combinations. Combinations of drugs act on different molecular pathways and achieve inhibition at separate areas. With new targeted therapies, average survival has improved considerably and death from local disease progression or airway compromise is less likely with improvement in quality of life. Unfortunately, the results remain poor in terms of survival.
AB - Introduction: Anaplastic thyroid cancer (ATC) is one of the most lethal diseases known to humans with a median survival of 5 months. The American Thyroid Association (ATA) recently published guidelines for the treatment of this dreadful thyroid malignancy. Areas covered: This review presents the current therapeutic landscape of this challenging disease. We also present the results from trials published over the last five years and summarize currently active clinical trials. Expert opinion: Recent attempts to improve the prognosis of these tumors are moving toward personalized medicine, basing the treatment decision on the specific genetic profile of the individual tumor. The positive results of dabrafenib and trametinib for ATC harboring the BRAF V600E mutation have provided a useful treatment option. For the other genetic profiles, different drugs are available and can be used to individualize the treatment, likely using drug combinations. Combinations of drugs act on different molecular pathways and achieve inhibition at separate areas. With new targeted therapies, average survival has improved considerably and death from local disease progression or airway compromise is less likely with improvement in quality of life. Unfortunately, the results remain poor in terms of survival.
KW - Anaplastic thyroid cancer
KW - Tyrosine-kinase inhibitors
KW - immune checkpoint inhibitors
KW - immunotherapy
KW - targeted therapy
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85141860113&partnerID=8YFLogxK
U2 - 10.1080/14737140.2022.2139680
DO - 10.1080/14737140.2022.2139680
M3 - Review article
C2 - 36283091
AN - SCOPUS:85141860113
SN - 1473-7140
VL - 22
SP - 1239
EP - 1247
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
IS - 11
ER -